BONTI, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2015-06-13
- Employees
- 1
- Market Cap
- -
- Website
- http://www.bonti.com
Clinical Trials
3
Active:0
Completed:3
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)Study of EB-001 in Facial Scar Reduction
Phase 2
Completed
- Conditions
- Mohs Surgery
- Interventions
- Drug: EB-001Drug: 0.9% Sodium Chloride Injection
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Bonti, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03346902
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Study to Evaluate EB-001 in Reducing Musculoskeletal Pain
Phase 2
Completed
- Conditions
- Musculoskeletal Pain
- Interventions
- Drug: EB-001Drug: Placebo
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Bonti, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT03193593
- Locations
- 🇺🇸
Lotus Clinical Research, Pasadena, California, United States
Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
Phase 2
Completed
- Conditions
- Glabellar Frown Lines (GL)
- Interventions
- Drug: EB-001 injectionDrug: Placebo injection
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Bonti, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02939326
- Locations
- 🇺🇸
Center For Dermatology Clinical Research, Inc., Fremont, California, United States
🇺🇸Steve Yoelin, MD Medical Associates, INC., Newport Beach, California, United States
News
No news found